Regulation of Neutrophil Function by Adenosine

被引:198
作者
Barletta, Kathryn E. [1 ]
Ley, Klaus [4 ]
Mehrad, Borna [2 ,3 ]
机构
[1] Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA
[2] Univ Virginia, Dept Med, Div Pulm & Crit Care Med, Carter Ctr Immunol, Charlottesville, VA USA
[3] Univ Virginia, Dept Microbiol, Div Pulm & Crit Care Med, Carter Ctr Immunol, Charlottesville, VA 22908 USA
[4] La Jolla Inst Allergy & Immunol, La Jolla, CA USA
关键词
blood cells; cytokines; chemotaxis; adhesion; host defense; NECROSIS-FACTOR-ALPHA; IV PHOSPHODIESTERASE INHIBITOR; SUPEROXIDE ANION GENERATION; A(2A) RECEPTOR ACTIVATION; A2; RECEPTORS; CYCLIC-AMP; POLYMORPHONUCLEAR LEUKOCYTES; LEUKOTRIENE BIOSYNTHESIS; PHYSIOLOGICAL MODULATOR; PULMONARY INFLAMMATION;
D O I
10.1161/ATVBAHA.111.226845
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adenosine is an endogenously released purine nucleoside that signals via 4 widely expressed G protein-coupled receptors: A(1), A(2A), A(2B), and A(3). In the setting of inflammation, the generation and release of adenosine is greatly enhanced. Neutrophils play an important role in host defense against invading pathogens and are the cellular hallmark of acute inflammation. Neutrophils both release adenosine and can respond to it via expression of all 4 adenosine receptor subtypes. At low concentrations, adenosine can act via the A(1) and A(3) adenosine receptor subtypes to promote neutrophil chemotaxis and phagocytosis. At higher concentrations, adenosine acts at the lower-affinity A(2A) and A(2B) receptors to inhibit neutrophil trafficking and effector functions such as oxidative burst, inflammatory mediator production, and granule release. Modulation of neutrophil function by adenosine is relevant in a broad array of disease models, including ischemia reperfusion injury, sepsis, and noninfectious acute lung injury. This review will summarize relevant research in order to provide a framework for understanding how adenosine directly regulates various elements of neutrophil function. (Arterioscler Thromb Vasc Biol. 2012;32:856-864.)
引用
收藏
页码:856 / 864
页数:9
相关论文
共 93 条
[21]   Neutrophils as sources of extracellular nucleotides: Functional consequences at the vascular interface [J].
Eltzschig, Holger K. ;
MacManus, Chiistopher F. ;
Colgan, Sean P. .
TRENDS IN CARDIOVASCULAR MEDICINE, 2008, 18 (03) :103-107
[22]   ATP release from activated neutrophils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function [J].
Eltzschig, Holger K. ;
Eckle, Tobias ;
Mager, Alice ;
Kueper, Natalie ;
Karcher, Christian ;
Weissmueller, Thomas ;
Boengler, Kerstin ;
Schulz, Rainer ;
Robson, Simon C. ;
Colgan, Sean P. .
CIRCULATION RESEARCH, 2006, 99 (10) :1100-1108
[23]  
FELSCH A, 1995, J IMMUNOL, V155, P333
[24]  
FIRESTEIN GS, 1995, J IMMUNOL, V154, P326
[25]   Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils [J].
Flamand, N ;
Surette, ME ;
Picard, S ;
Bourgoin, S ;
Borgeat, P .
MOLECULAR PHARMACOLOGY, 2002, 62 (02) :250-256
[26]   Adenosine, a potent natural suppressor of arachidonic acid release and leukotriene biosynthesis in human neutrophils [J].
Flamand, N ;
Boudreault, S ;
Picard, S ;
Austin, M ;
Surette, ME ;
Plante, H ;
Krump, E ;
Vallée, MJ ;
Gilbert, C ;
Naccache, P ;
Laviolette, M ;
Borgeat, P .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (02) :S88-S94
[27]   Purines and neutrophil leukocytes [J].
Fredholm, BB .
GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1997, 28 (03) :345-350
[28]   AdenosineA(2A) receptors mediate the inhibitory effect of adenosine on formyl-Met-Leu-Phe-stimulated respiratory burst in neutrophil leucocytes [J].
Fredholm, BB ;
Zhang, Y ;
vanderPloeg, I .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1996, 354 (03) :262-267
[29]  
Gadangi P, 1996, J IMMUNOL, V156, P1937
[30]   A3 adenosine receptors in human neutrophils and promyelocytic HL60 cells:: A pharmacological and biochemical study [J].
Gessi, S ;
Varani, K ;
Merighi, S ;
Cattabriga, E ;
Iannotta, V ;
Leung, E ;
Baraldi, PG ;
Borea, PA .
MOLECULAR PHARMACOLOGY, 2002, 61 (02) :415-424